VBI Vaccines, Inc.
|Number of Estimates|
VBI Vaccines, Inc. is a biopharmaceutical company, which engages in the development of vaccines for infectious disease and immuno-oncology. The firm focuses on the prevention and treatment of hepatitis B through its product pipeline, the Sci-B-Vac and VBI-2601. It also develops enveloped virus-like particle (eVLP) platform technology, which allows the development of eVLP vaccines that closely mimic the target virus to elicit a potent immune response. The company was founded on July 9, 2015 is headquartered in Cambridge, MA.
Market Cap: 457 Million
Primary Exchange: NASDAQ
Shares Outstanding: 231 Million
Float: 205 Million
Sector: Health Technology
Longest drawdown: 1803 trading days
From: 2013-07-31 To: 2020-05-28
|Ex-Date||Payment Date||Record Date||Declared Date||Amount||Flag||Dividend Type||Qualified||Indicated|
|Ex-Date||Declared Date||Record Date||Payment Date||Ratio||To Factor||For Factor|